You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a rapid response nucleic acid vaccine strategy for coronavirusepidemics

    SBC: ORLANCE, INC            Topic: NIAID

    ABSTRACT In response to the emerging COVID-19 (SARS-CoV-2) pandemic, this supplement proposal to R44 AI138733- 01 will leverage our cutting-edge nucleic acid vaccine strategies, some of which that were developed under this parent grant. Here, we request supplement funding to develop candidate COVID-19 DNA and RNA vaccines expressing optimally designed immunogens for the SARS-CoV-2 spike protein. N ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Integrating a suite of mental health apps for depression in a healthcare setting.

    SBC: Adaptive Health, Inc.            Topic: 104

    Abstract Depression is common, imposing a tremendous societal burden in terms of cost, morbidity, quality of life, and mortality. The great majority of people with depression are treated in primary care, however outcomes remain poor. There have been two broad attempts to address this problem. One is collaborative care, which uses care managers to coordinate patient care. Collaborative care can be ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer

    SBC: Cancer Targeted Technology LLC            Topic: 102

    PROJECT ABSTRACT Prostate-Specific Membrane Antigen (PSMA) is an ideal tumor biomarker as it is expressed on andgt;90% of all prostate cancers and expression increases as the cancer progresses. Cancer Targeted Technology (CTT) has developed a unique phosphoramidate-based scaffold that binds irreversibly to PSMA leading to andgt; 90% rapid internalization and selective accumulation in tumor cells. ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States

    SBC: VIRTICI LLC            Topic: 500

    Project Summary The objective of this proposal is to create a Mountain West region technology Accelerator Hub to conduct research on developing, implementing, and testing a comprehensive collateral and consulting offering for promoting biomedical entrepreneurship, technology transfer, management, small business finance, and additional business skills needed to commercialize basic research to enhan ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients

    SBC: Syntrix Biosystems, Inc.            Topic: NHLBI

    This SBIR Fast-Track proposal meets the objectives of NHLBI Small Business Topic of Special Interest for Fiscal Year 2017 Code HLS17-04. Myelodysplastic syndromes (MDS) are genetically and morphologically diverse hematopoietic neoplasms that arise from a small pool of mutant clones within hematopoietic stem and progenitor compartments. Only three drugs have received regulatory approval specificall ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Product and Regulatory Development of a Needle-Free Hemodialysis Access Port

    SBC: HEALIONICS CORPORATION            Topic: NHLBI

    Product and Regulatory Development of a Needle-Free Hemodialysis Access Port PROJECT SUMMARY Objective: The overall objective of this SBIR Phase IIB Bridge Award project is to advance a new Needle-FreeHemodialysis Access Port to the stage of IDE approval for a subsequent first in Human study. Significance: For the nearly 500,000 End Stage Renal Disease (ESRD) kidney failure patients in the US on h ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Prophylactic Onchocerciasis Vaccine

    SBC: PAI LIFE SCIENCES INC            Topic: NIAID

    Humanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the Global Burden of Disease Studyindicate thatmillion cases of onchocerciasisleading tomillion cases of vision impairmentoccur worldwide every yearThe goal of this project is to develop a safe and effecti ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients

    SBC: LUMITHERA INC            Topic: NEI

    As the population continues to age, degenerative ocular diseases become increasingly common and create a tremendous burden on the health care system. Age-related macular degeneration (AMD) represents a significant problem with 10-11 million patients at risk to progress to severe vision loss in the U.S. alone and the prevalence of AMD is expected to double by 2020. The dry and wet forms of the dise ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Improvement of Preclinical Oxygen Imager JIVA-25

    SBC: O2M TECHNOLOGIES LLC            Topic: NCI

    Abstract JIVA-25 is a small footprint 25 mT preclinical oxygen imager based on the principles of electron paramagnetic resonance oxygen imaging. JIVA-25 can provide oxygen maps in tissues with 1 mm spatial resolution, 1 torr oxygen resolution, and 1-10 min temporal resolution. No other competing method can provide accurate noninvasive pO2 maps with such precision. In tumors, accurate real-time pO2 ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government